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Abstract 25 
Objectives 1) To compare three internationally established criteria for drugs with anticholinergic 26 
properties (DAPs) and their associated factors in long-term care facilities.  2) To investigate the 27 
association between use of DAPs and psychological well-being (PWB) or mortality. 28 
Design Cross-sectional study and 1-year follow-up of all-cause mortality.  29 
Setting and Participants Of all 4449 residents living in long-term care facilities in Helsinki in 30 
2011, 2432 (≥ 65 years of age) participated after exclusion of residents with severe dementia.    31 
Measurements Data on demographics, medication use, and active diagnoses were collected by 32 
trained staff using structured questionnaires.  DAP use was defined by the following three 33 
international criteria: Chew’s list, the Anticholinergic Risk Scale (ARS), and the Anticholinergic 34 
Drug Scale (ADS).  The total number of DAPs was counted and referred to as anticholinergic 35 
burden.  PWB was assessed by a questionnaire and yielded a score ranging from 0 to 1.  Mortality 36 
data was retrieved from central registers.    37 
Results Of all participants, 85% were DAP users according to at least one of the three criteria used.  38 
Overlap between the three criteria was only moderate.  DAP users were younger and a larger 39 
proportion of them had better cognition.  However, they suffered more often from depression and 40 
other psychiatric diagnoses than nonusers.  DAP users had lower PWB scores than those not using 41 
DAPs, and PWB decreased linearly in the overlapping groups from nonusers to those using DAPs 42 
according to all three criteria.  The total number of DAPs used predicted mortality.    43 
Conclusions and Implications DAP use and PWB appear to be negatively associated.  When 44 
combining several criteria of DAPs, their burden predicted mortality.  Clinicians should carefully 45 
consider the potential benefits and harms when prescribing DAPs to older persons.  46 
 47 
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Introduction 48 
Drugs with anticholinergic properties (DAPs) are a heterogenous group of medicines.  They are 49 
considered as potentially harmful to older people because of their adverse effects peripherally and 50 
especially on the nervous system.1  Some important peripheral effects of DAPs include dryness of 51 
mouth, tachycardia, constipation and blurred vision.2,3  Undesired central side-effects of DAPs 52 
include increased risk for functional decline,4,5 falls,6 cognitive decline,7-10 and increased use of 53 
health services.11,12  Central adverse effects are known to be dose-dependent.  Accordingly, a higher 54 
anticholinergic burden is associated with a higher risk of adverse outcomes.5  DAPs are still widely 55 
used among frail older people living in residential care.13-15  DAPs are frequently used to manage 56 
various symptoms such as urinary incontinence, anxiety, and pain.16  The effect of DAPs on 57 
mortality has also been investigated but most studies have not shown a clear relationship between 58 
DAP use and mortality. 6,13,17-19 However, there are a few studies showing contradictory 59 
findings.8,20,21  60 
Residents in long-term care generally suffer from multiple chronic diseases and have deficits in 61 
functioning and cognition.  Management should thus aim towards symptom relief and palliative 62 
care, and quality of life (QOL) should be one of the most important goals of care.  Psychological 63 
well-being (PWB) is a means to evaluate one dimension of QOL.  To our knowledge, few studies 64 
have investigated the association between DAPs and QOL.  There is some evidence that residents 65 
using DAPs living in long-term care facilities also have lower PWB than those not using DAPs.15,22     66 
Several lists classifying anticholinergic drugs and their anticholinergic properties have been 67 
developed.4,5  We aimed to compare these DAP lists with each other.  To explore outcomes of 68 
DAPs, we chose the three most highly cited lists used internationally according to Web of Science 69 
and Google Scholar.5,23-25 These three lists were created in various ways.  While Chew’s list is 70 
based on measuring in vitro the serum anticholinergic activity of drugs commonly used by older 71 
persons,23 the Anticholinergic Drug Scale (ADS) is based on expert consensus24 and the 72 
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Anticholinergic Risk Scale (ARS) on a literature review and expert opinion25.  Although some 73 
studies have compared some anticholinergic criteria,4,5,26,27 there is still no international consensus 74 
regarding which of these lists would be applicable in research or in clinical practice.                 75 
The objectives of the current study were to investigate 1) how the use of DAPs according to any of 76 
the anticholinergic lists studied (Chew’s list, ADS and ARS) is associated with participant 77 
characteristics, 2) how participant DAP use according to these anticholinergic lists is overlapping, 78 
and 3) how participant DAP use according to these anticholinergic lists and their combinations or 79 
the total number of DAPs according to any criteria (referred to as DAP burden) are associated with 80 
self-rated health, PWB, and mortality.   81 
Methods 82 
This study was part of a larger study28,29 that investigated the nutritional status, medication use, and 83 
associated factors of older persons in all long-term care facilities in Helsinki.  During October and 84 
November 2011, cross-sectional data were collected from all older persons living permanently 85 
either in assisted living facilities or in nursing homes, including group homes for persons with 86 
dementia (n=4449).  Of all participants, 1097 were excluded because of patient refusal or dementia 87 
and without a close proxy to give informed consent.  In addition, residents with severe dementia 88 
(score 3 on Clinical Dementia Rating (CDR) scale memory item)30 (n=920) were excluded to 89 
include only those capable of responding to PWB.  A total of 2432 participants thus remained in the 90 
study.  Written informed consent was obtained from each participant or their closest proxy in case 91 
of significant cognitive decline (CDR 2).  The study was approved by the Helsinki University 92 
Central Hospital Ethics Committee.  93 
In each care unit, a trained nurse assessed the resident’s status by retrieving background data from 94 
medical records on demographic factors and diagnoses (chronic conditions and acute illnesses) and 95 
performed the assessments and interviews according to a structured questionnaire.  Each resident 96 
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was assessed over the course of one day.  All data concerning medication use was point prevalence 97 
on the same day.  98 
Nutritional status was assessed by the Mini-Nutritional Assessment (MNA).31  Participants were 99 
respectively divided into "malnourished" (<17 points), "at risk for malnutrition" (17-23.5 points), 100 
and “well-nourished” (>23.5 points).  Cognitive function was evaluated by the memory item of the 101 
CDR scale (0-0.5, no or possible memory problems; 1, mild memory loss; 2, moderate memory 102 
loss), which is a validated method to assess dementia stage.30 The residents’ ability to move was 103 
assessed by the question “Is the resident able to move inside?” (1=yes, 2= no, needs a stick or a 104 
walker, 3= no, needs another person’s assistance, 4= no, unable to walk at all).  Those in groups 1 105 
and 2 were considered able to walk independently inside.  Dependence in activities of daily living 106 
(ADL) was assessed by a 4-point scale according to the CDR “personal care” item (1=fully capable 107 
of self-care, 2=needs occasional prompting, 3=requires assistance in dressing, personal hygiene, and 108 
keeping of personal belongings, 4=requires much help with personal care; often incontinent).30 109 
Those in groups 3 and 4 were considered as dependent on a caregiver’s help.  Participants’ 110 
morbidity was assessed by the Charlson Comorbidity Index (CCI).32      111 
Medication use was retrieved from medical charts during the assessment day.  The resident was 112 
considered a regular drug user if the medical chart indicated a regular sequence for the drug dosage.  113 
Only regularly used DAPs were considered in determining the DAP burden.   All medications were 114 
coded according to the Anatomical Therapeutic Chemical (ATC) Classification System of the 115 
World Health Organization (WHO) (WHO Collaborating Center for Drug Statistics 116 
Methodology).33 All DAPs used by the participants were listed and classified according to the 117 
following three anticholinergic lists: Chew’s list,23 ADS,24 and ARS25.  According to Chew’s list, 118 
22 of 107 medications studied are demonstrated to have anticholinergic activity ranging from low 119 
(+) to high (+++).  The ADS rates 117 drugs as anticholinergic ranging from potentially 120 
anticholinergic (1) to markedly anticholinergic (3).  The ARS classifies 49 drugs having 121 
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anticholinergic potential ranging from moderate (1) to very strong (3).  The three lists consist partly 122 
of different selection of anticholinergic drugs.  The criteria for defining the anticholinergic potential 123 
or the defined burden also differ from each other.  Thus, the anticholinergic activity and the 124 
anticholinergic burden is difficult to compare between the lists.  In this study, the total number of 125 
DAPs is referred to as DAP burden.    126 
QOL was evaluated by self-rated health and PWB questionnaire.  Resident’s subjective health (self-127 
rated health) was evaluated by the following question: “How do you rate your current health 128 
status?” (1=healthy, 2= quite healthy, 3=unhealthy, 4=very unhealthy).  Those responding “healthy” 129 
or “quite healthy” were considered as having good self-rated health. The PWB scale has been used 130 
in several studies since 1989.34-36 It has good test-retest reliability35, good prognostic validity34 and 131 
good concurrent validity with The World Health Organization Quality of Life – scale (WHOQOL-132 
Bref ).37  The residents were asked six questions as follows: 1. Are you satisfied with your life? 133 
(yes/no); 2. Do you have zest for life? (yes/no); 3. Do you feel needed? (yes/no); 4. Do you have 134 
plans for the future? (yes/no); 5. Do you suffer from loneliness? (seldom or never/sometimes/often 135 
or always); 6. Do you feel depressed? (seldom or never/sometimes/often or always).  The answers 136 
were then given 0 points (“no” in questions 1-4 and “often or always” in questions 5-6), 0.5 points 137 
(“sometimes” in questions 5-6) or 1 point (“yes” in questions 1-4 and “seldom or never” in 138 
questions 5-6).  The PWB score was then generated by adding the points together and dividing the 139 
sum by the number of questions answered, thus yielding a score between 0 to 1 (0 represents the 140 
poorest and 1 the best well-being). 141 
We divided the participants into DAP users and nonusers according to the use of at least one DAP 142 
included in one or more of the three lists mentioned above.  We then generated a Venn diagram 143 
creating three overlapping groups of DAP lists as mentioned above (Figure 1).  Only 14 drugs were 144 
considered as DAPs according to all three criteria.  The number of DAPs used regularly by any 145 
criteria by each participant was counted. 146 
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Mortality was retrieved from central registers over a 1-year follow -up.  147 
Statistical analyses 148 
Data are presented as absolute numbers, percentages for categorical variables and as means with 149 
standard deviations or ranges for continuous variables.  The DAP users of according to any criteria 150 
were compared with nonusers with X2-test for categorical variables and t-test or permutation test for 151 
continuous variables.  152 
The relationship between DAPs and mortality or PWB was analyzed using linear regression 153 
analysis and logistic models.  Models included gender, age and Charlson index as covariates. 154 
Shapiro-Wilk statistics were used to test the normality of variables. Stata 15.0, StataCorp LP 155 
(College Station, TX, USA) statistical package was used for the analysis. 156 
Results 157 
The Venn diagram (Figure 2) illustrates the DAP users’ position in the various overlapping groups 158 
according to Chew`s list, ADS and ARS.  Of all participants, 2079 (85%) used at least one DAP 159 
according to any of the three criteria; 353 (15%) did not use DAPs at all.  Of DAP users, 1243 160 
(60%) used at least one DAP according to ARS, 1334 (64%) used at least one DAP according to 161 
Chew’s list, and 1652 (79%) were administered at least one DAP according to ADS. Furthermore, 162 
of DAP users, 700 (34%) used one or more DAPs according to only one list, 1379 (66%) used 163 
DAPs according to at least two lists, and 771 (37%) used one or more DAPs according to all three 164 
lists.   165 
Compared with nonusers, DAP users were younger and had better cognition, but more often 166 
suffered from depression, other psychiatric disorders, and Parkinson disease.  The CCI of DAP 167 
users was significantly higher than the respective value of nonusers (2.4 vs. 2.1, p<0.001).  Those 168 
using DAPs were more often at risk for malnutrition than nonusers (p=0.049).  The mean number of 169 
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regularly used drugs was significantly higher among DAP users than nonusers (9.3 vs. 5.4, p 170 
<0.001).  While DAP users suffered more often from dry mouth than nonusers (p=0.011), no 171 
difference between the groups was observed regarding constipation, diarrhea, or vomiting.  No 172 
significant differences existed between the groups with respect to sex distribution, education, 173 
dependency on another person’s help, or ability to walk inside (Table 1).   174 
A larger proportion of participants not using DAPs considered their self-rated health as good 175 
compared to those using DAPs (70% vs. 64%, p=0.039). Those not using DAPs also had a 176 
significantly higher PWB score than those using DAPs (0.77 vs. 0.68, p<0.001).  There was no 177 
difference in mortality between users and nonusers (18% vs. 20%, p=0.44) (Table 1).   178 
In a further analysis regarding the relationship between DAP use and psychological well-being and 179 
mortality, the groups were compared to each other according to one, two, or three criteria of DAP 180 
use.  Using DAPs according only to one criteria did not seem to affect PWB compared to nonusers, 181 
except for those using DAPs defined only by Chew’s list, whose PWB was significantly lower than 182 
the PWB of nonusers.  When using DAPs defined by two or three criteria, the participants did have 183 
significantly lower PWB compared to nonusers (p<0.001, adjusted for sex, age and comorbidity).  184 
There was no significant difference in mortality between the overlapping groups (p=0.41, adjusted 185 
for sex, age, and comorbidity) (Figure 3).  We further adjusted for number of medications, and the 186 
findings were essentially the same (data not shown).  187 
When exploring the total burden of DAPs (i.e. the total number of DAPs according to any of the 188 
three criteria used), PWB decreased as a linear trend as the number of DAPs increased (p<0.001 for 189 
linearity, adjusted for sex, age, and comorbidity).  The risk of mortality increased along with 190 
increasing number DAPs used (p=0.006 for linearity, adjusted for age, sex, and comorbidity) 191 
(Figure 4).  We further adjusted for number of medications, and the findings were essentially the 192 
same (data not shown).  193 
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We further performed sensitivity analyses by excluding all those with depression diagnosis. All the 194 
findings were essentially the same (data not shown).      195 
Discussion 196 
Our study revealed that DAP use seems to have an inverse association with the PWB of older 197 
people living in long-term care facilities.  Even though the DAP users were younger and had fewer 198 
cognitive problems than nonusers, their self-rated health and PWB was poorer than that of nonusers.  199 
DAP users suffered more often from depression and other psychiatric illnesses and had more 200 
comorbidities than nonusers.  PWB decreased linearly as the number of DAPs increased.  By 201 
investigating the overlapping of various criteria of DAPs among DAP users, we observed that 202 
neither the criteria alone nor a combination of two or three criteria predicted mortality.  Instead, the 203 
total number of DAPs used according to any of these criteria (i.e. the total anticholinergic burden) 204 
was associated with increased risk of mortality.        205 
Our study has several strengths and limitations.  One strength of the study is the relatively large 206 
sample of older, frail people living in long-term care facilities in Helsinki.  The data were collected 207 
by trained nurses by the same procedure in every participating unit.  The information on 208 
demographic data, medication use and medical diagnoses were retrieved from each participant`s 209 
medical records.  The mortality data were retrieved from central registers, which is 100% complete 210 
in Finland.  The PWB scale is a well-validated tool even among older people with cognitive decline.  211 
Another strength was the use of three internationally well-known criteria in defining DAPs.  212 
Furthermore, we also focused on the burden of DAPs of each participant by counting the total 213 
number of DAPs according to any of the three lists.      214 
One limitation of our study is its cross-sectional nature.  Thus, it is not possible to draw definite 215 
conclusions between DAP use and PWB or mortality.  The total time exposure of each individual 216 
medication is not known, as the data were collected as a point prevalence over one day and the 217 
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follow-up time was one year.  The original indication of the drugs is also unknown.  Only regularly 218 
administered drugs were calculated in the total anticholinergic load, not drugs given pro re nata.  219 
All drugs were administered by nurses and adherence should thus be nearly 100%.  We also were 220 
unable to use the burden defined by the various scales as the three scales are not congruent in 221 
defining the anticholinergic burden; this can be considered a limitation.  Our study demonstrates 222 
how relative the definitions and burden are according to various DAP scales.   There may be 223 
confounding by indication bias regarding the use of DAPs and PWB.  It is possible that PWB was 224 
poorer because of DAP use, or because the participants were given DAPs to manage some 225 
underlying disease (e.g. depression) that might have lowered their PWB score.  However, our 226 
sensitivity analyses showed that the results were the same when those with depression were 227 
excluded. The results are consistent with our previous study from the same study population15 in 228 
which we observed that possible underlying depression did not explain the poorer PWB among 229 
DAP users.   230 
DAP users were younger as in previous studies.38,39  DAP users suffered less often from cognitive 231 
problems compared to nonusers.  In contrast to our previous study15, in the current study DAP users 232 
had more comorbidities according to the CCI than nonusers.  One possible explanation is that the 233 
ADS contains a large number of very common drugs for coronary and heart diseases. 234 
Our study demonstrates how the three scales differ from each other.  Our combined list from three 235 
scales includes 138 DAPs but only 14 drugs are common in all scales.  Of these 14 drugs, the most 236 
commonly used drugs were olanzapine and clozapine.  The ADS scale has a high number of DAPs 237 
that are not included in other lists.  Chew’s list is quite compact but contains drugs frequently used 238 
by older people (e.g. mirtazapine and citalopram).  Consistent with previous studies comparing 239 
various DAP scales, the scales seem to predict different outcomes from each other.12,40  However, to 240 
our knowledge there are no prior studies exploring how DAP use overlaps in real-life settings or 241 
how the number of DAPs used according to the three scales impacts on important outcomes.  242 
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When comparing overlapping groups, we did not observe any significant differences in all-cause 243 
mortality between the groups, even after adjusting for age, sex, and CCI.  This can be explained by 244 
the fact that the anticholinergic burden does not necessarily increase even though DAP use is 245 
defined by multiple criteria.  Instead, when considering the total number of DAPs defined by any of 246 
the three criteria, an association with increased mortality was demonstrated even after adjusting for 247 
age, sex, and CCI.  This is a new finding compared to most prior studies. 6,13,17-19 Only one prior 248 
scale, the Anticholinergic Cognitive Burden Scale (ACB)41, has shown in several studies predictive 249 
value on mortality.6,8,19,21 The ACB scale includes 88 DAPs, thus emphasizing that higher number 250 
of potential DAPs may have impact on mortality.  There was a linear relationship between mortality 251 
and higher number of these drugs used.  252 
To our knowledge, despite the importance of PWB of older persons living their last years in long-253 
term care facilities, there is still a lack of studies investigating the relationship between DAP use 254 
and PWB.  While Kolanowski et al.42 found no association between anticholinergic burden and 255 
engagement in activity (an indicator of QOL in persons with dementia), Teramura-Grönblad et al.22 256 
and Aalto et al.15 found an association between PWB and DAP use.  In an Australian study 257 
assessing older people living in residential care facilities, an association was found between the use 258 
of potentially harmful medicines defined by the Drug Burden Index and the self-reported QOL 259 
measured with the Quality of Life-Alzheimer´s disease questionnaire.43  A small American study 260 
among community-dwelling older adults with dementia also revealed an association between DAP 261 
use and lower health-related QOL.44 Our current study supports the earlier findings of the 262 
association between DAPs and poorer PWB.    263 
Conclusions and Implications 264 
The use of DAPs seems to have a negative association with PWB of older and vulnerable people 265 
living in institutionalized care.  The DAP burden was linearly associated with poorer PWB.  Neither 266 
a single criterium alone nor a combination of two or three criteria predicted mortality.  Instead, we 267 
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found a weak, linear association between the total number of DAPs and increased mortality.  The 268 
most appropriate criteria for DAPs in assessing the anticholinergic load of older people remains 269 
thus far unknown and further studies are needed.  270 
 271 
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Table 1. Participants’ characteristics according to usage of drugs with anticholinergic properties (DAPs). 297 
 Using no 
DAPs  
n=353 (15%) 
Using one or 
more DAPs 
n=2079 (85%) 
p-value1 
Female, n (%) 254 (72) 1568 (75) 0.16 
Age, mean (SD2) 86 (7) 84 (8) <0.001 
Education <8 yrs, n (%) 201 (57) 1144 (55) 0.50 
Depression, n (%) 37 (10) 489 (24) <0.001 
Other psychiatric diagnosis, n (%) 18 (5) 291 (14) <0.001 
Parkinson disease, n (%) 9 (3) 138 (7) 0.003 
CCI3, mean (SD2) 2.1 (1.4) 2.4 (1.5) <0.001 
MNA4, n (%)   0.049 
At risk for malnutrition (17-23.5 points), n 
(%) 
206 (59) 1353 (65)  
Moderate cognitive decline (CDR 2)5, n (%) 154 (44) 679 (33) <0.001 
Dependent for personal care (CDR personal 
care class 2-3)6, n (%) 
285 (81) 1724 (83) 0.32 
Ability to walk inside, n (%) 117 (50) 1115 (54) 0.22 
Number of drugs used regularly, mean (SD2) 5.4 (2.9) 9.3 (3.4) <0.001 
Dry mouth, n (%) 36 (10) 319 (15) 0.011 
Constipation, n (%) 125 (35) 719 (35) 0.76 
Diarrhea, n (%) 32 (9) 253 (12) 0.094 
Vomiting, n (%) 12 (3) 97 (5) 0.29 
Self-rated health good, n (%) 246 (70) 1331 (64) 0.039 
PWB7, mean (SD2) 0.77 (0.23) 0.68 (0.26) <0.001 
One-year mortality, n (%) 71 (20) 374 (18) 0.44 
 298 
 299 
 
1 p-value, adjusted for age, sex, comorbidity, CDR and dependency for personal care 
2 SD= standard deviation 
3 CCI= Charlson Comorbidity Index (Charlson et al. 1987)32 
4 MNA= Mini-Nutritional Assessment (Vellas et al. 1999)31 
5 CDR=Clinical Dementia Rating, ”memory” item (Hughes et al. 1982)30 
6 CDR, ”personal care” item (Hughes et al. 1982)30 
7 PWB= psychological well-being (Routasalo et al. 2009)36 
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orphenadrine, oxazepam, oxcarbazepine, oxycodone, pancuronium, phenelzine, pimozide, piperacillin, 
prednisolone, prednisone, procyclidine, propantheline, protriptyline, pyrilamine, scopolamine, 
sertraline, theophylline, tramadol, triamcinolone, triamterene, triazolam, trihexyphenidyl, 
trimipramine, valproic acid, vancomycin, warfarin 
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Legends to figures 354 
Figure 1.  355 
Venn diagram showing how the three scales on drugs with anticholinergic properties (DAP) 356 
overlap. Anticholinergic Risk Scale (ARS)25, Anticholinergic Drug Scale (ADS)24 and Chew’s list23 357 
 358 
Figure 2.  359 
Venn diagram showing how the participants fell into groups using drugs with anticholinergic 360 
properties (DAP) in the overlapping groups of three DAP scales. DAP users N=2079 (85%), non-361 
users N=353 (15%) 362 
DAP users by: a=Anticholinergic Risk Scale (ARS);25 b=Chew’s list (Chew);23 c=Anticholinergic 363 
Drug Scale (ADS);24 ab=ARS+Chew; ac=ARS+ADS; bc=Chew+ADS; abc=ARS+Chew+ADS.  364 
 365 
Figure 3.  366 
A, Psychological well-being (PWB) in groups according to use of drugs with anticholinergic 367 
properties (DAP) by various criteria and how the overlapping groups predicted PWB (p<0.001).   368 
None=not using any DAP; Anticholinergic Risk Scale (ARS)25; Chew’s list (Chew)23; 369 
Anticholinergic Drug Scale (ADS)24 370 
B, Relative risk for mortality is presented in respective groups (p=0.41).     371 
The relationships between DAPs and PWB or mortality were analyzed using linear regression 372 
analysis (mean) and logistic models (relative risk). Models included sex, age, and Charlson 373 
comorbidity index as covariates.            374 
 375 
Figure 4.  376 
A, Psychological well-being (PWB) in groups using no drugs with anticholinergic properties 377 
(DAPs) or using 1 to 5 or more DAPs. The higher the number of DAPs the lower is PWB (p<0.001 378 
for linearity). 379 
B, Relative risk for mortality is presented in respective groups. The number of DAPs has a linear 380 
relationship with mortality (p=0.006 for linearity).  381 
The relationships between number of DAPs and PWB or mortality were analyzed using linear 382 
regression analysis (mean) and logistic models (relative risk).  Models included sex, age, and 383 
Charlson comorbidity index as covariates.    384 
                                                                                                                                                                      385 
 386 
 387 
 388 
 389 
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